Thermo Fisher Sells Microbiology Unit for $1.075 Billion to Astorg — Thermo Fisher Scientific Inc.

Event summary

Thermo Fisher Scientific agreed to sell its microbiology business to Astorg for approximately $1.075 billion, including a $50 million seller note.
The microbiology business generated $645 million in revenue in 2025 and is part of Thermo Fisher's Specialty Diagnostics segment.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Thermo Fisher anticipates the sale will be dilutive to adjusted earnings per share by $0.15 in the first full year following the close.

The big picture

Thermo Fisher's divestiture reflects a strategic move to streamline its portfolio, focusing on higher-growth areas while monetizing non-core assets. The sale to Astorg, a leading pan-European private equity firm, underscores the ongoing trend of private equity firms acquiring specialized healthcare businesses. With annual revenue exceeding $45 billion, Thermo Fisher's decision highlights the broader industry dynamic of large conglomerates optimizing their holdings for shareholder value.

What we're watching

Integration Challenges: The pace at which Astorg can integrate the microbiology business into its portfolio and maintain customer relationships.
Financial Impact: How Thermo Fisher deploys the additional capital from the sale to create shareholder value.
Regulatory Approvals: Whether the transaction receives timely regulatory approvals and closes as expected in the second half of 2026.